So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
So-Young International Inc.NASDAQ: SY
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 5.1% from a year ago
Cash & equivalents stood at CN¥467.57M at the end of Q1 FY2026, up 5.1% from a year earlier and down 3.2% from the prior quarter. Over 3 fiscal years it compounded at -11.4% a year.
Context
- Cash & equivalents amounted to 17.6% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CNY · from the balance sheet
- Latest · FY2025
- 483.2M CNY
- Year-over-year change
- -17.8%
- 4-year CAGR
- -22.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 483.2M | -17.8% |
| FY2024 | 2024-12-31 | 587.75M | +37.9% |
| FY2023 | 2023-12-31 | 426.12M | -38.6% |
| FY2022 | 2022-12-31 | 694.42M | -47.9% |
| FY2021 | 2021-12-31 | 1.33B | — |
Cash & Equivalents vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +5.1% is the 6th highest of 11, against a peer median of +6.9%.
- Cash & equivalents amounts to 17.6% of total assets for SY, versus a peer median of 18.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CN¥467.57M CNY | +5.1% | -11.4% | 17.6% | |
| Mar 2026 | $265.77M USD | +76.1% | +13.3% | 41.6% | |
| Mar 2026 | $231.01M USD | +18.6% | -7.1% | 79.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M USD | +15.9% | -8.8% | 95.6% |
| Apr 2026 | $85.3M USD | -58.4% | +17.5% | 7.8% | |
| Mar 2026 | $84.28M USD | +502.5% | -13.3% | 3.2% | |
| Mar 2026 | $75.08M USD | -2.1% | -17.3% | 18.6% | |
| Mar 2026 | $65.39M USD | -4.6% | -24.2% | 41.7% | |
| Mar 2026 | $38.09M USD | -39.4% | -9.5% | 14.2% | |
| Feb 2026 | $25.73M USD | +134.1% | -15.7% | 17.6% | |
| Mar 2026 | $1.91M USD | -55.3% | -4.3% | 0.7% | |
| Peer median (excluding SY) | — | +6.9% | -9.2% | 18.1% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.33B | 694.42M | 426.12M | 587.75M | 483.2M |
| Short-term Investments | 408.95M | 875.96M | 900.82M | 599.04M | 453.76M |
| Net Receivables | 110.45M | 170.29M | 80.38M | 226.25M | 68.65M |
| Inventory | 91.81M | 120.48M | 118.92M | 151.75M | 233.54M |
| Other Current Assets | 18.19M | 17.29M | 147.45M | 159.56M | 246.39M |
| Total Current Assets | 2.03B | 1.92B | 1.72B | 1.72B | 1.49B |
| Property, Plant & Equipment (Net) | 220.19M | 179.08M | 235.19M | 318.12M | 545.54M |
| Goodwill | 540.69M | 540.69M | 540.69M | 684K | 684.43K |
| Intangible Assets | 193.96M | 169.28M | 145.25M | 126.62M | 144.19M |
| Long-term Investments | 252.5M | 227.96M | 261.02M | 280.28M | 274.93M |
| Tax Assets | 47.52M | 64.74M | 78.03M | 84.95M | 69.36M |
| Other Non-current Assets | 48.1M | 99.29M | 310.49M | 285.1M | 131.08M |
| Total Non-current Assets | 1.3B | 1.28B | 1.49B | 1.01B | 1.17B |
| Total Assets | 3.33B | 3.2B | 3.21B | 2.74B | 2.65B |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 0 | 29.83M | 69.77M | 39.81M |
| Tax Payables | 48.57M | 74.58M | 56.89M | 0 | 0 |
| Deferred Revenue | 190.26M | 181.67M | 195.21M | 190.37M | 292.65M |
| Other Current Liabilities | 256.23M | 239.93M | 288.77M | (119.6M) | 276.34M |
| Total Current Liabilities | 712.4M | 538.04M | 540.42M | 630.21M | 784.55M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 38.58M | 30.99M | 25.08M | 19.76M | 10.62M |
| Deferred Revenue (Non-current) | (38.58M) | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 38.58M | 30.99M | 1.54M | 1.26M | 2.78M |
| Total Non-current Liabilities | 100.93M | 51.97M | 112.83M | 146.22M | 196.89M |
| Total Liabilities | 813.33M | 590.01M | 653.25M | 776.43M | 981.44M |
| Common Stock | 267K | 273K | 275K | 290K | 294.19K |
| Retained Earnings | (272.37M) | (346.62M) | (330.17M) | (885.84M) | (1.18B) |
| Accumulated OCI | (63.56M) | 33.13M | 52.04M | 31.56M | 59.83M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 70.85M | 109.94M | 117.19M | 119.61M | 115.58M |
| Total Equity | 2.52B | 2.61B | 2.56B | 1.96B | 1.67B |
| Total Debt | 105.89M | 71.26M | 145.77M | 239.88M | 299.9M |
| Net Debt | (1.23B) | (623.16M) | (280.35M) | (347.87M) | (183.3M) |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.